AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC

Condition: Non-Small Cell Lung Cancer

Sponsor: AbbVie

Full Title
Protocol M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Study Treatment
c-MET targeting antibody-drug conjugate telisotuzumab adizutecan in combination with investigational anti-PD-1 antibody budigalimab or standard chemo/immunotherapy.

Eligibility/Info

Part 1:

• 1L Cohort: No prior systemic therapy in the advanced/metastatic setting
• 2L Cohort: Participants without an actionable genetic alteration must have progressed on (or be considered ineligible for) platinum-based chemotherapy or immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy). Participants with an actionable genetic alteration (other than EGFR) must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alteration or platinum-based chemotherapy.

Part 2:

• Participants must have had no prior systemic therapy for locally advanced or metastatic NSCLC.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage